Hyperkalemia Treatment Guidelines

Classification by Severity

STEP 1 - Stabilize the Cardiac Membrane (Emergent, ECG changes present)

• Calcium gluconate: 10 mL of 10% solution IV over 1-3 minutes (preferred for peripheral IV access)
• Calcium chloride: 3-5 mL of 10% solution IV (more elemental calcium per ampule, but causes skin necrosis if it infiltrates - use central line only)
• Effect is rapid and nearly immediate; if no ECG improvement in 3-5 minutes, repeat the dose
• Effect is transient (30-60 min) - must follow with redistribution therapies
• Caution in digoxin toxicity: calcium potentiates digoxin cardiotoxicity

STEP 2 - Shift K+ Into Cells (Redistribution - Temporizing)

A. Insulin + Dextrose (fastest and most reliable)

• Regular insulin 10 units IV + 50 mL of 50% dextrose (D50W) as a bolus
• Follow with D5W infusion at 100 mL/hour to prevent late hypoglycemia
• K+ begins to fall within 15 minutes, peak effect at ~60 minutes
• Key cautions:
  • Never give dextrose without insulin - in patients with inadequate endogenous insulin, hyperglycemia can paradoxically raise K+
  • If blood glucose >300 mg/dL, insulin can be given without dextrose
  • Monitor glucose closely; hypoglycemia is common in renal failure (prolonged insulin half-life)
  • Lispro/aspart may cause less hypoglycemia in kidney failure as they are not renally metabolized

B. Nebulized Albuterol (Beta-2 Agonist)

• 20 mg nebulized over 10 minutes (use concentrated 5 mg/mL formulation)
• Onset ~30 minutes; effect is additive to insulin
• The dose needed for K+ lowering is much higher than the bronchodilator dose
• IV albuterol 0.5 mg (available in Europe) is equivalent to 20 mg nebulized
• Low-dose IV epinephrine infusion can also be used in emergencies (e.g., post-massive transfusion) with added inotropic benefit

C. Sodium Bicarbonate

• Lowers K+ by enhancing renal K+ excretion, not by cell shift (useful in patients with residual kidney function)
• Onset within 15 minutes when metabolic acidosis is present
• Indications: metabolic acidosis (especially serum bicarb <10 mmol/L) AND the patient has residual kidney function
• Not indicated as routine emergency monotherapy in patients without residual kidney function (ESKD/dialysis patients)
• Does not enhance the potassium-lowering effects of insulin or albuterol - no additive benefit in combination

STEP 3 - Remove K+ from the Body (Definitive Therapy)

A. Diuretics

• Loop and thiazide diuretics - effective if adequate kidney function exists
• Loop diuretics preferred when eGFR <30 mL/min
• Not useful in oliguric AKI or ESKD

B. Hemodialysis

• Most effective modality for K+ removal
• Indicated for severe hyperkalemia with oliguria, AKI, or ESKD
• Cannot typically be initiated fast enough to replace emergency measures above - stabilize with Steps 1-2 first

C. Potassium Binders (oral/rectal - adjunct and chronic prevention)

• SPS: not approved for chronic management; evidence base is weak (mostly small, low-quality studies); colonic necrosis risk is real especially with sorbitol
• Patiromer and SZC: FDA-approved for chronic management of hyperkalemia; multiple RCTs show ~1 mEq/L sustained reduction in K+; particularly useful to allow continuation/up-titration of RAASi in CKD and heart failure
• None of the binders should be used as monotherapy for acute or emergency hyperkalemia - use only as adjuncts to Steps 1-2

Non-Emergent Management (No ECG Changes)

1. Stop exogenous K+ (IV fluids, dietary sources, salt substitutes)
2. Dietary K+ counseling - avoid high-K+ foods, salt substitutes containing KCl
3. Discontinue or dose-reduce causative drugs where possible: NSAIDs, ACE inhibitors, ARBs, potassium-sparing diuretics, trimethoprim, heparin
4. Treat underlying cause (e.g., fludrocortisone for hypoaldosteronism)
5. Ensure effective diuretic therapy - loop diuretics especially when eGFR <30 mL/min
6. Oral NaHCO3 to treat metabolic acidosis
7. Consider K+ binders - particularly to enable guideline-directed RAASi use in CKD/HF patients

Special Clinical Situations

Hyperkalemia in CKD/Heart Failure on RAASi

Perioperative/Anesthetic Considerations

• Elective surgery should be deferred until hyperkalemia is corrected
• Succinylcholine is contraindicated - depolarizing blockade causes additional K+ release
• Avoid potassium-containing IV solutions (e.g., lactated Ringer's)
• Avoid metabolic or respiratory acidosis - use controlled ventilation
• Monitor neuromuscular function closely - hyperkalemia accentuates NMB effects
• Morgan and Mikhail's Clinical Anesthesiology, 7e

Digoxin-Toxic Patients

• Calcium is relatively contraindicated - calcium potentiates digoxin cardiotoxicity ("stone heart" syndrome)
• Consider Digibind (digoxin-specific antibody fragments) instead

Summary Algorithm

Hyperkalemia
    |
    ├── ECG changes or K+ >6.5 mEq/L → EMERGENT
    │       1. Calcium gluconate 10 mL 10% IV (stabilize membrane)
    │       2. Insulin 10U + D50W IV (shift)
    │          + Albuterol 20 mg nebulized (shift, additive)
    │       3. Remove: Diuretics / Dialysis / Binders (adjunct)
    │
    └── No ECG changes, K+ 5.5-6.5 mEq/L → NON-EMERGENT
            - Stop K+ sources, dietary counseling
            - Remove causative drugs
            - Loop diuretics (if renal function intact)
            - Oral NaHCO3 (if metabolic acidosis)
            - Chronic K+ binders (patiromer or SZC) to enable RAASi

• NKF Primer on Kidney Diseases, 8e (p. 128-129)
• Morgan and Mikhail's Clinical Anesthesiology, 7e (p. 2180-2181)
• Sabiston Textbook of Surgery, 11e (Box 33.5, p. 602)
• GUARDIAN-HK European Steering Committee, 2025 [PMID: 40685253]
• Huang et al., Drugs, 2025 - Novel Potassium Binders Meta-analysis [PMID: 40542996]